Sun Pharmaceuticals delivered astonishing 33.8% YoY Net Profit Growth !!

Today Sun-pharmaceutical has come up with it’d Q4 24 quarterly result and result is quite outstanding on Year on Year basis.

In Revenue Sun Pharma has gown by 9.6% on YoY basis and -3.2% on QoQ basis. Total income of the company stood at 125884 which is 11.4% higher than last year and -0.3% QoQ. Overall expense has also grown slightly and stood at 96,716 which is 8.8% higher than last year.

Net profit come the company stood at 26,545 which is 33.8% higher then last year and 5.2% higher then previous quarter.

There is also a growth in EPS on YOY and QoQ basis. EPS stood at 11.1 which was 10.5 last year and 8.3 previous quarter.

Over all numbers looks reasonable.

After the result announcement in the last hour of the market Sun Pharma announced its numbers and we saw a spike in the price. Price seems to be breaking the zone highlighted in yellow towards the upside.

Overview of Sun Pharmaceutical

Sun Pharmaceutical Industries Ltd., founded in 1983 by Dilip Shanghvi, has evolved into one of the largest and most influential pharmaceutical companies globally. The company’s mission is to provide high-quality, affordable medications that improve patient health worldwide, while its vision is to become a global leader in the pharmaceutical industry through innovation and excellence. Over the decades, Sun Pharmaceutical has achieved significant milestones, demonstrating its commitment to growth and excellence.

One of the critical phases in Sun Pharmaceutical’s growth trajectory was its expansion beyond India, establishing a robust global presence. Today, the company operates in over 100 countries, with key markets including the United States, Canada, Western Europe, Japan, Australia, and several emerging economies. This extensive reach ensures that Sun Pharmaceutical can meet diverse patient needs and contribute to global healthcare improvement.

Sun Pharmaceutical’s product portfolio is vast and diverse, encompassing a wide range of therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology, and diabetology. The company is known for its generic medications, specialty pharmaceuticals, and over-the-counter (OTC) products, catering to various healthcare requirements. This diversification ensures that Sun Pharmaceutical remains resilient and adaptable in the dynamic pharmaceutical landscape.

Strategic acquisitions and mergers have been pivotal in Sun Pharmaceutical’s expansion and consolidation within the industry. Noteworthy acquisitions include the purchase of Ranbaxy Laboratories in 2014, which significantly bolstered Sun Pharmaceutical’s market presence and product offerings. Other significant acquisitions include Taro Pharmaceuticals, which enhanced its footprint in dermatology and specialty pharmaceuticals, and Pharmalucence, which expanded its capabilities in sterile injectable products.

Sun Pharmaceutical’s journey from a small Indian pharmaceutical company to a global powerhouse exemplifies its dedication to quality, innovation, and patient-centricity. Through its strategic growth initiatives and a diverse product portfolio, the company continues to play a crucial role in enhancing global healthcare.

Disclaimer :- All the facts & the figure presented in the article are taken from internet and all the opinion presented in the article are authors personal opinion and this is not at all an investment suggestion. Before any buying and selling in the stock, please check with your investment advisor.